Stay updated on Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.

Latest updates to the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page
- Check2 days agoChange DetectedNew latest revision v3.6.5 appears in the history, replacing the previous v3.6.4 and signaling an administrative update to the record.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded entries indicate the study record now includes Adverse Events, Baseline Characteristics, Participant Flow, and Outcome Measures (Results), along with the Study Status. The entry also notes that the submission was returned on 2026-07-29 with Quality Control Review not concluded.SummaryDifference0.9%

- Check16 days agoChange DetectedA new revision entry v3.6.4 was added to the study history, and the previous revision v3.6.3 was removed from the visible history list, indicating an update to the record's metadata.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe study record history now shows a new revision entry labeled v3.6.3, replacing the previous v3.6.2. This reflects an updated version of the record on ClinicalTrials.gov.SummaryDifference0.1%

- Check45 days agoChange DetectedThe latest version returned on 2026-06-24 adds sections such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Document Section, Arms and Interventions, and Study Design to the history, and notes that Quality Control Review Has Not Concluded. This reflects expanded documentation in the study record and a current QC status for ongoing review.SummaryDifference1%

- Check59 days agoChange DetectedThe study record history now displays that recruitment has closed and adds a new version tag, Revision: v3.6.0, while removing the previous Revision: v3.5.5.SummaryDifference0.4%

Stay in the know with updates to Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.